• Online Features  This Article  • References  • Full text PDF  • Correction  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (12)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

William H. Perry, MD
Department of Internal Medicine University of Kansas School of Medicine 1001 N Minneapolis Wichita, KS 67214

Arch Dermatol. 1983;119(11):874.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

Methotrexate has known teratogenic effects when received by a woman during the first trimester of pregnancy, and theoretically, the fetus is at risk when either parent has received the drug before conception. Studies of women whose pregnancies occurred subsequent to chemotherapy, including methotrexate for trophoblastic neoplasms, showed no increase in fetal loss or congenital malformation.^1,2 There are only anecdotal reports of normal children born to women whose husbands were treated with methotrexate.³I briefly review the case of a male patient who fathered a normal child while receiving methotrexate therapy.

Report of a Case.—

A 34-year-old man was treated for Reiter's syndrome with 10/25 mg/wk of oral methotrexate from January 1973 through February 1975. During an 18-month remission, the disease exacerbated and 25 mg/wk of oral methotrexate therapy was resumed from August 1977 through July 1978. In February 1978, the patient said his wife was . . . [Full Text PDF of this Article]

CiteULike    Connotea    Delicious    Digg    Facebook    Reddit    Technorati    Twitter     What's this?